StockMarketWire.com - Renalytix AI said US regulators had set a national price for its kidney disease test.

Under the 2020 fee schedule, the price for the KidneyIntelX product with a unique reimbursement code was set at $950 by the Centers for Medicare and Medicaid Services.

The price would become effective on 1 January and remain in effect for a three-year term until December 2022.

'Historically, coverage and pricing have lagged innovative test launches by three to five years,' chief commercial officer Tom Mclain said.

'We believe this accelerated timeframe for KidneyIntelX pricing reflects the benefit of improved patient outcomes by delaying or preventing the onset of end-stage renal disease and kidney failure, as well as the expected cost reductions that can be delivered to healthcare systems across the US.'


At 9:45am: [LON:RENX] share price was +20p at 307p



Story provided by StockMarketWire.com